Abstract:Background: Osteosarcoma is a common primary bone malignancy prevalent among adolescents and young adults. PTEN-induced kinase 1 (PINK1) regulates Parkinson's disease, but its role in cancers is unknown. Objective: This study was designed to analyze the mechanism by which PINK1 affects osteosarcoma using bioinformatics and cell experiments. Materials and methods: The gene expression profiles were downloaded from the TARGET database. Several online databases were used to analyze the expression and protein‒protein interaction networks. CCK-8 cell viability assays and cisplatin treatment were used to assess cell activity with or without cisplatin treatment. Acridine orange/ethidium bromide (AO/EB) fluorescence staining was used to calculate the percentage of apoptotic cells. Results: Through bioinformatics analysis, we found that high expression of PINK1 was associated with poor prognosis in patients with osteosarcoma, and PINK1 inhibited apoptosis and promoted proliferation pathways. Next, we found that both PINK1 mRNA and protein levels were upregulated in osteosarcoma tissues. Additionally, we found that PTEN was reduced, while FOXO3a was markedly increased in osteosarcoma, suggesting that FOXO3a and not PTEN induced the overexpression of PINK1. CCK-8 and clonogenic assays showed that the knockdown of PINK1 decreased the growth of U2OS osteosarcoma cells. Ki67 immunofluorescence staining revealed that reduced cell proliferation in U2OS cells resulted in the depletion of PINK1. In addition, our AO/EB staining results indicated that the knockdown of PINK1 resulted in an increase in apoptotic cells and increased the levels of cleaved caspase-3. Furthermore, our experiments revealed that cisplatin promotes OS cell apoptosis by downregulating PINK1. Conclusion: Collectively, our findings demonstrate that PINK1 is crucially involved in osteosarcoma and suggests that it can promote the apoptosis of OS cells as the downstream target gene of cisplatin.

Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.

Inhibitory Effects of PARP-1 Inhibitor on Growth of Human Osteosarcoma Cells.

Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer.

Effect of PLK1 inhibitor on proliferation of osteosarcoma cells and its mechanism

Targeted PLK1 suppression through RNA interference mediated by high‐fidelity Cas13d mitigates osteosarcoma progression via TGF‐β/Smad3 signalling

Polo-like kinase 1 as a potential therapeutic target for osteosarcoma.

Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment

Plk1 As A Potential Drug Target in Cancer Therapy

Lycorine Induces Apoptosis and G1 Phase Arrest Through ROS/p38 MAPK Signaling Pathway in Human Osteosarcoma Cells in Vitro and in Vivo

Targeting Oral Squamous Cell Carcinoma with Combined Polo-Like-Kinase-1 Inhibitors and γ-Radiation Therapy

Aurora B kinase as a novel molecular target for inhibition the growth of osteosarcoma.

Kinome-Wide Screening with Small Interfering RNA Identified Polo-like Kinase 1 As a Key Regulator of Proliferation in Oral Cancer Cells

Plumbagin induces G2/M arrest and apoptosis and ferroptosis via ROS/p38 MAPK pathway in human osteosarcoma cells

Retraction Of: A005, a Novel Inhibitor of Phosphatidylinositol 3-Kinase/mammalian Target of Rapamycin, Prevents Osteosarcoma-Induced Osteolysis.

The Interaction of SKP2 with P27 Enhances the Progression and Stemness of Osteosarcoma

LINC01060 knockdown inhibits osteosarcoma cell malignant behaviors in vitro and tumor growth and metastasis in vivo through the PI3K/Akt signaling

Proanthocyanidin B2 Inhibits Proliferation and Induces Apoptosis of Osteosarcoma Cells by Suppressing the PI3K/AKT Pathway

Cooperative blockade of FLT3 and ALK synergistically suppresses growth of osteosarcoma

Identification of XD23 as a potent inhibitor of osteosarcoma via downregulation of DKK1 and activation of the WNT/β-catenin pathway

PINK1 regulates apoptosis of osteosarcoma as the target gene of cisplatin

2-methylbenzoyl berbamine, a multi-targeted inhibitor, suppresses the growth of human osteosarcoma through disabling NF-κB, ERK and AKT signaling networks